The development of the UK's SEP/FRAND landscape since Unwired Planet v Huawei – part two
27. Februar 2026
Lydia is a senior counsel in the Patents team in our London office and has a depth of knowledge and experience in both the Life Sciences & Healthcare, and Technology, Media and Communications sectors.
Lydia has a broad practice, advising clients on international strategy in relation to telecommunications and tech, medical device and pharmaceutical patent litigation. In particular she has represented clients in many of the leading cases involving SEP and FRAND matters.
Lydia has litigated in the High Court and Court of Appeal, co-ordinated multi-jurisdictional disputes and advised on EPO opposition proceedings. She has also advised on and co-ordinated the first ever case to be heard in the Nordic-Baltic Regional Division of the Unified Patent Court.
Lydia's clients include leading international telecommunication companies, and global pharmaceutical and medical device companies.
News & Insights: Lydia Birch
Patents Technology & Life Sciences
Klicken Sie hier für Details
The development of the UK's SEP/FRAND landscape since Unwired Planet v Huawei – part one
30. Januar 2026
Briefing
Synapse - AI in Life Sciences
Klicken Sie hier für Details
Revocation of life sciences patents in the UPC
The Unified Patent Court (UPC), active since June 2023, is seeing strong uptake in pharma and biotech. Revocation decisions show a balanced 50:50 win rate for patentees and challengers. Key legal standards on novelty, obviousness, and inventive step are emerging, though some aspects remain unclear. Strategic use of the UPC offers broad enforcement, but revocation risks are higher for single-patent portfolios. Legal uncertainties, like the Bolar exemption, still need clarification.
17. Juni 2025
4 von 5 Insights
